Meeting
2023 ASCO Annual Meeting
Utility of Ki67 in guiding adjuvant abemaciclib therapy for patients with hormone receptor (HR)-positive, early breast cancer (EBC).
Authors
Rima Patel
Icahn School of Medicine at Mount Sinai, New York, NY
Rima Patel , Nadeem Bilani , Amy Tiersten , Joseph A. Sparano
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Local/Regional/Adjuvant
Track
Breast Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 559)
DOI
10.1200/JCO.2023.41.16_suppl.559
Abstract #
559
Poster Bd #
389
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
State-of-the-art management of HER2-negative early breast cancer: Treatment patterns among healthcare professionals and concordance with expert recommendations.
First Author: Marie N. Becker
Poster
2023 ASCO Annual Meeting
Indirect treatment comparison of first-line CDK4/6-inhibitors in post-menopausal patients with HR+/HER2- metastatic breast cancer.
First Author: Joseph J Zhao
Poster
2022 ASCO Annual Meeting
Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6).
First Author: Thomas Meyskens
Poster
2022 ASCO Annual Meeting
Open-label, phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre- and postmenopausal women with locally advanced or metastatic ER+/HER2− breast cancer and an ESR1 mutation after progression on prior therapies.
First Author: Senthil Damodaran